Dendritic cells (DC) are promising tools for the immunotherapy of cancer. The induction of
tumor-specific T cells and clinical regressions have already been observed in early phase I/II
vaccination trials. As DC vaccination is now facing trials with larger patient collectives it
becomes increasingly important to obtain large numbers of cells suitable for therapeutic
applications under labor-and cost-effective conditions. We describe here a procedure that
uses a novel cell separator (Elutra™, Gambro BCT) to enrich monocytes from an entire …